All News Items
Talk im Cube: International Cooperation and Funding programs in Life Sciences
15.05.2025 / We are excited to continue also in 2025 the Talks in the Cube starting with a further expert discussion focused on International cooperation and Funding programs in Life Sciences. … more
Helmholtz Drug Discovery Conference kommt nach Berlin
24.04.2025 / Vom 28. bis 30. April treffen sich führende Wirkstoffforscher*innen und Unternehmen am Max Delbrück Center. Auf der Helmholtz Drug Discovery Conference 2025 werden sie über RNA-basierte Therapien, PROTACs, KI für die Medikamentenentwicklung und Chemoproteomik diskutieren und neue Kooperationen schmieden. … more
Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
24.04.2025 / Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials. … more
How the heart and blood vessels influence organs
24.04.2025 / The Helmholtz Institute for Translational AngioCardioScience (HI-TAC) invites attendees to its first Symposium on April 28 and 29, 2025. Researchers from around the world will meet at Heidelberg University to discuss how the heart and blood vessels communicate with the rest of the body to shape health. … more
Consortium of African and European research institutions secures €1.5 million grant to build capacity for early drug discovery in sub-Saharan Africa
23.04.2025 / An African and European research consortium receives €1.5 million from the European Union and additional resources from the Swiss government to support the accumulation of knowledge, skills and innovative capacities for drug discovery in sub-Saharan Africa. The associated project “RAFIKI”, which launched in January 2025, will tackle pressing public health challenges and build new avenues for cooperation between African and European researchers. … more
Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
25.03.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further develop its promising lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. … more
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
20.03.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing. … more
Inflammatory messenger fuels Alzheimer’s
18.03.2025 / Researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer’s disease. The study was published in the journal “Nature Aging.” … more
New treatment approach for rare blood cancer of the skin
10.03.2025 / Researchers from Medical University of Vienna, Charité Berlin and Max Delbrück Center have identified the CD74 protein as a new drug target to treat deadly skin lymphoma. The study was published in the “British Journal of Dermatology.” … more
Inequality raises disease risk, especially for women
07.03.2025 / A study led by researchers at the Max Delbrück Center has found that low socioeconomic status raises the risk of cardiovascular disease in women more so than in men. The study underlines the importance of gender-specific prevention. … more
“Jugend forscht” at Campus Berlin-Buch
03.03.2025 / From better 3D printers for biological structures to soil remediation with microorganisms – in the 60th round of “Jugend forscht,” regional students presented their exciting research projects on the Berlin-Buch campus. … more
Not all heart inflammation is the same
25.02.2025 / A group of Berlin researchers in collaboration with international scientists have found differences in heart inflammation caused by COVID-19, anti-COVID-19 vaccination, and non-COVID-19 myocarditis. The find paves the way for more personalized therapies, they report in “Nature Cardiovascular Research.” … more
Access to high-performance computing for businesses
20.02.2025 / Helmholtz invests €18 million in AI innovation ecosystems: Nine Helmholtz centers open their High-Performance Computing infrastructure to companies and connect businesses with their AI experts. More than €2 million will go to the Max Delbrück Center. … more
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
07.02.2025 / Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC). … more
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
31.01.2025 / Tubulis (a joint spin-off of the FMP and the Ludwig-Maximilians-Universität Munich) announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa trial (NCT06657222). The study is evaluating TUB-030, Tubulis’ next-generationntibodydrug conjugate (ADC), in patients with advanced solid tumors. The ADC targets 5T4, an oncofetal antigen expressed in a broad range of solid tumors. The program was developed using Tubulis’ proprietary Tubutecan linker-payload platform, which enables superior biophysical properties for precise and sustained on-tumor payload delivery. … more
Heike Graßmann new State Secretary in Saxony
17.01.2025 / The Max Delbrück Center congratulates Professor Heike Graßmann, who has served as Administrative Director of the research center since 2018, on her appointment as State Secretary for Science, Culture, and Tourism in Saxony. Graßmann will assume her new role in Dresden on February 1, 2025. … more
FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
15.01.2025 / Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial (‘SANTANA-225’) of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). … more
Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
15.01.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales. … more
Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
13.01.2025 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced the expansion of their existing Lutetium-177 based collaboration with a global supply agreement for Actinium-225 (Ac-225). Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical research and development activities on innovative alpha radiotherapeutics. … more
Developing a CRISPR therapy for muscular dystrophy
07.01.2025 / Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in “Nature Communications” now paves the way for first-in-human clinical trials. … more
Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW
13.12.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge diagnostic tools including 68Ga-PSMA-11 in Japan. For GalliaPharm®, Novartis Pharma K.K., will manage safety information and distribution of the product in Japan. … more
Leibniz Prize awarded to Ana Pombo
11.12.2024 / The German Research Foundation (DFG) has announced that biochemist Ana Pombo from the Max Delbrück Center is among this year’s winners of the Gottfried Wilhelm Leibniz Prize. With a grant of €2.5 million, the Leibniz Prize is one of the highest endowed research prizes in Germany. … more
Inspiring and connecting: “Talk im Cube”
09.12.2024 / For almost a year, “Talk im Cube” has been bringing science and business together on the Campus Berlin-Buch … more
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
06.12.2024 / Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the signing of a global supply agreement for the medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). … more
Eckert & Ziegler: Changes in the Executive Board and Supervisory Board
03.12.2024 / The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment. … more
The Max Delbrück Center bids farewell to Thomas Sommer
03.12.2024 / For three decades, Thomas Sommer conducted research at the Max Delbrück Center and shaped its development: as a scientist, ombudsman, committee representative, and interim board member. On December 6, the center will honor him with a symposium on his favorite topic — the cell's recycling system. … more
Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
02.12.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). The test production demonstrated that the choice of technology was appropriate to achieve the expected parameters of the product. … more
Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)
28.11.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand®, by the European Commission (EC). This enables the use of the radiopharmaceutical medicinal product Theralugand® in routine clinical applications throughout the European Economic Area (EEA). … more
Berlin goes USA
21.11.2024 / Strengthening transatlantic economic relations: Berlin delegation trip to the USA - with a focus on life science and health … more
Max Delbrück Center signs licence agreement with Kite, a Gilead Company, for Sleeping Beauty Transposon System
20.11.2024 / Supported by its technology transfer partner Ascenion, Max Delbrück Center has entered into a licensing agreement with Kite providing the company with non-exclusive rights to use the transposon system for the genetic engineering of T cells. … more
Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024
14.11.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 million or € 1.12 per share. … more
Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225
13.11.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix totaling up to € 20 million within approximately two years, as well as access to a higher availability of Ac-225. … more
Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
08.10.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its GMP grade non-carrier added Lutetium-177 chloride (n.c.a. Lu-177) for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers. … more
Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
02.10.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pentixapharm AG became legally effective. All shares in Pentixapharm AG held by Eckert & Ziegler have thus been legally transferred from Eckert & Ziegler SE to Pentixapharm Holding AG. … more
OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
27.09.2024 / Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025 … more
Einladung: Zukünfte der Künstlichen Intelligenz – Szenarien für die künftige Arbeitswelt
09.09.2024 / Keynote im Rahmen der Jahreskonferenz des Bundesverbands Deutscher Innovations-, Technologie- und Gründerzentren e.V. (BVIZ) … more
A new drug target for psychiatric disorders
05.09.2024 / Misha Kudryashev’s lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia. Published in “The EMBO Journal,” the study points to a potentially new target for therapeutics. … more
New in Berlin: tumor immunologist Johannes Huppa
02.09.2024 / Johannes Huppa has taken up the professorship for tumor immunology at Charité – Universitätsmedizin Berlin as of September 1. The T-cell receptor expert will also conduct research at the Max Delbrück Center in Berlin-Buch and the German Consortium for Translational Cancer Research (DKTK). … more
New clues on how the heart makes arteries
30.08.2024 / A team in the labs of Holger Gerhardt and Norbert Hübner at the Max Delbrück Center has elucidated how new arteries form, potentially helping to improve therapies aimed at regenerating heart muscle after a heart attack or stroke. The research was published in “Circulation Research.” … more
Surprising mechanism of lupus kidney damage identified
15.08.2024 / A team led by Charité – Universitätsmedizin Berlin, German Rheumatology Research Center and the Max Delbrück Center have defined key cells behind severe kidney damage in lupus. The research, published in “Nature,” can inform future antibody therapies. … more
Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
13.08.2024 / Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study. The contract covers the supply of the entire European patient base from the state-of-the-art facility in Berlin. In addition, Eckert & Ziegler will also be a provider of the crucial starting material in the form of their high-purity, non-carrier added GMP-grade Lutetium-177 (Lu-177). … more
Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
05.08.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide generator GalliaPharm®. The generator was first launched in 2014 and is today approved in 17 European countries and many other key international markets. With the EC approval, an additional 14 countries in the European Economic Area (EEA) will gain access to GalliaPharm®, once national approval procedures have been completed. Consequently, it will soon be the first generator for the production of Gallium-68 commercially available in the entire EEA. … more
Events
all events
29.04.2025, 10:00-
29.04.2025, 16:00
Campus Bike Day: Bike Fitting & Bicycle Coding
15.05.2025, 17:00-
15.05.2025, 19:00
International Cooperation and Funding programs in Life Sciences
23.05.2025, 09:00-
23.05.2025, 18:00
WEITERBILDUNGSTAG LABOR 4.0 FÜR TECHNISCHE ANGESTELLTE UND LABORANT*INNEN